[Diabetes and arterial hypertension]

Area of Science:

• Endocrinology and Cardiovascular Medicine
• Metabolic Syndrome Research

Context:

• Type II diabetes and hypertension are prevalent comorbidities in adults, particularly in developed nations.
• Obesity exacerbates the cardiovascular risks associated with diabetes and hypertension, creating a significant public health challenge.
• The co-occurrence of these conditions elevates the risk of cardiovascular complications far beyond that of isolated hypertension.

Purpose:

• To highlight the increased cardiovascular risk in patients with coexisting Type II diabetes, hypertension, and obesity.
• To discuss the contributing factors to this elevated risk, including hyperglycemia, metabolic syndrome (Syndrome X), and hyperinsulinemia.
• To emphasize the necessity of aggressive non-pharmacological and pharmacological therapeutic strategies.

Summary:

• The combination of Type II diabetes, hypertension, and obesity leads to a substantially higher risk of cardiovascular complications.
• Factors such as hyperglycemia, metabolic syndrome (hyperlipemia, hyperuricemia, thrombophilia, altered Na(+)-H+ membrane exchanges), and hyperinsulinemia contribute to atherosclerosis and clinical events.
• Effective management necessitates aggressive therapeutic approaches, often involving multiple antihypertensive medications.
• Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers are recommended, especially for hypertensive patients with diabetes and proteinuria.

Impact:

• Aggressive blood pressure control is universally recognized as the most effective strategy for improving prognosis in this high-risk population.
• Understanding the interplay between diabetes, hypertension, obesity, and metabolic factors is key to developing targeted interventions.
• The findings underscore the importance of comprehensive management strategies to mitigate cardiovascular events in patients with these comorbidities.